Hey @stephencca, I agree with some of what you say, not all the good things that are happening with the company now, were hatched by this management. The sale of Metrics (unfortunate but very necessary) was done by the previous CEO and current Chairman, swiftly and for a good price, so kudos to them. Also the DTC strategy for dermatology was also hatched by the previous CEO but the execution was poor resulting in negative revenue in 1HF 2023. As far as Womens Health products, the previous CEO was responsible for buying Nexstellis for a huge price and committing the company to large launch costs and the launch was poorly executed, without the purchase of the TherapeuticsMD products by current CEO, Women's Health would be years away from delivering a profit.
And finally, it's not my style to put other investors down for poorly timed decisions they made and I hope that this mngt team can deliver a profit for them.
MYX Price at posting:
$5.62 Sentiment: Buy Disclosure: Held
(20min delay)